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An important determinant of cellular resistance to chemotherapeutic O
6-alkylating agents, which comprise methylating and
chloroethylating agents, is the ability of cells to repair alkylation damage at the O
6-position of guanine in DNA. This is achieved
by a speciﬁc DNA repair enzyme O
6-alkylguanine DNA-alkyltransferase. In this study O
6-alkylguanine DNA-alkyltransferase
expression was measured in human breast tumours using both biochemical and immunohistochemical techniques. O
6-
alkylguanine DNA-alkyltransferase activity was then compared with known clinical prognostic indices to assess the potential
role of O
6-alkylguanine DNA-alkyltransferase in predicting the behaviour of this common malignancy. The application of both
biochemical and immunohistochemical techniques was feasible and practical. Most breast tumours expressed high levels of O
6-
alkylguanine DNA-alkyltransferase. Immunohistochemical analysis showed marked variation in expression not only between
individuals but also within individual tumours, and in the same patient, between metastases and between primary tumour and
metastatic site. O
6-alkylguanine DNA-alkyltransferase activity in tissue extracts signiﬁcantly correlated not only with
immunohistochemical staining intensity determined by subjective quantitation, but also with measures of protein levels using a
computerised image analysis system including mean grey (P50.001), percentage of cells positive for O
6-alkylguanine DNA-
alkyltransferase (P50.001), and integrated optical density (P50.001). O
6-alkylguanine DNA-alkyltransferase expression did not
correlate with any of the established clinical prognostic indicators for current treatment regimens. However,
immunohistochemical offers a rapid and convenient method for assessing potential utility of O
6-alkylating agents or O
6-
alkylguanine DNA-alkyltransferase inactivating agents in future studies of breast cancer treatment.
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Standard ﬁrst-line chemotherapy for advanced breast cancer results
in disease regression in the majority of patients but these responses
are rarely complete or sustained (Clemons et al, 1997). Patients
with relapsed or persistent disease often require further chemother-
apy and there is, therefore, a continuing need to develop new
treatments. One strategy is the biochemical modulation of tumour
drug resistance, an important area of experimental and clinical
cancer therapeutics.
The chemotherapeutic O
6-alkylating agents are well established
in oncology and are a component of high-dose therapy regimens
currently used in the treatment of metastatic (Peters et al, 1994;
Antman, 2001), and high-risk adjuvant breast cancer (Bengala et
al, 2001). These agents include methylating (e.g. Dacarbazine and
Procarbazine) and several chloroethylating agents (e.g. Carmustine
and Semustine).
Both in vitro and in vivo experiments have demonstrated that an
important determinant of resistance to O
6-alkylating agents is the
ability of cells to repair alkylation damage at the O
6-position of
guanine in DNA. This is achieved by the DNA repair protein,
O
6-alkylguanine DNA-alkyltransferase (ATase), through the cova-
lent transfer of the alkyl group from the O
6 position of guanine
to a cysteine residue within the active site of the ATase protein,
a reaction that is stoichiometric and autoinactivating (Pegg, 1990,
1994; Pegg et al, 1995).
The relationship between the sensitivity of human tumours in
vivo and ATase levels is complex (D’Incalci et al, 1998; Phillips
and Gerson, 1999) and has as yet not been fully elucidated,
although pre-clinical studies have demonstrated a correlation
between tumour ATase levels and sensitivity to nitrosoureas
(Margison and O’Connor, 1990; Pegg, 1990). Several authors have
measured ATase expression in human breast tumours and report
low (Cao et al, 1991), moderate (Chen et al, 1992) and high activ-
ity (Musarrat et al, 1995). Considerable heterogeneity of ATase
levels is also reported for other tumour types (Gander et al,
1999). High levels of ATase activity have been correlated with a
poor prognosis in early breast cancer (Citron et al, 1994) and
may in part explain the relative resistance of metastatic breast
cancer to treatment with O
6-alkylating agents. A number of strate-
gies are currently under clinical trial in breast cancer patents using
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www.bjcancer.comeither alkylating agents (NCIC, 2001) or pseudosubstrates (Spiro et
al, 1999) to deplete tumour ATase and hence increase tumour
chemosensitivity. Indeed recent work has used changes in tumour
ATase expression for calculating the effective dose of ATase modu-
lators in Phase I studies (Spiro et al, 1999).
In view of these ongoing strategies for ATase depletion it is
important to have useful measures of tumour ATase activity.
Conventional assays of ATase expression in extracts of biopsy
material are extremely sensitive but produce tissue-average values
and take no account of cellular heterogeneity (Lee et al, 1991;
Watson and Margison, 2000). In order to assess the inter- and
intra-cellular distribution of the protein a sensitive and highly
speciﬁc antiserum to recombinant human ATase (Lee et al, 1992)
was used in formalin-ﬁxed parafﬁn embedded breast tumours.
Having shown the technique to be feasible ATase expression was
measured in snap-frozen breast tumours by both conventional
biochemical and by immunohistochemical (IHC) assay. IHC
analyses of ATase expression scored both subjectively and objec-
tively with a computerised quantitative digital IHC technique
were then compared. The computerised system should be less
subjective, more quantitative and potentially more sensitive than
conventional human visualisation methods. Indeed, computerised
scoring is already established for the analysis of oestrogen and
progesterone receptor status in human breast tumours (Van Agth-
oven et al, 1995).
Finally, statistical analyses were performed to determine if ATase
expression measured by assay or IHC were correlated either with
each other or with other clinical prognostic parameters present
in these patients. The mechanisms of regulation of expression of
ATase are poorly understood and whilst there is no a priori basis
for comparing prognostic variables with ATase, the possibility of
a correlation between it and other variables was considered a
worthwhile question.
MATERIALS AND METHODS
Samples
Formalin-ﬁxed samples from primary breast tumours Tissue
specimens from patients undergoing surgical treatment for primary
breast cancer at Bradford Royal Inﬁrmary were ﬁxed in buffered
formalin and embedded in wax. Sections stained with haematoxylin
and eosin (H&E) were used for routine pathological diagnosis
while other sections were stained for ATase (see below).
Alcohol-ﬁxed samples from primary breast tumours Samples
for resected tumours obtained at the time of primary surgery at
the Christie Hospital were snap-frozen in liquid nitrogen and
stored until subsequent assay. Samples were rapidly defrosted in
batches of 10 and each tumour divided into two parts. Half was
immediately assayed for ATase activity and the other half ﬁxed
in 70% alcohol for subsequent IHC. These sections were assessed
for ATase using a conventional IHC scoring method and an image
analysis system. Clinical, staging and prognostic information was
available for all these patients.
Measurement of ATase activity
The preparation of tissue extracts and quantitation of ATase activ-
ity was performed as previously described (Watson and Margison,
2000).
IHC staining and quantitation
Sections (3 mm) were prepared, mounted onto 3-aminopropyl-
triethoxysilane (Sigma Chemical Co. Ltd., Poole, UK) coated
slides, dried overnight, dewaxed in xylene and rehydrated through
graded alcohols (100%, 90%, 70% and 40% ethanol). Sections of
formalin ﬁxed material were microwaved for 25 min in 1 l of
0.1 M citric acid pH 6.0 at this stage to retrieve antigenic sites.
After washing in 50 mM TBS (pH 7.6) endogenous peroxidase
activity was blocked with 3% H2O2 in Tris-buffered saline (TBS)
for 15 min at room temperature and washing in running water
followed by TBS. The sections were incubated with 5% normal
swine serum in TBS for 20 min at room temperature to block
nonspeciﬁc binding of IgG, and were then incubated with polyclo-
nal rabbit anti-human ATase antiserum (1:1500) in TBS overnight
at 48C. Control sections were incubated with pre-adsorbed serum
at the same dilution. After washing in TBS the slides were incu-
bated with biotinylated swine anti-rabbit serum at 1:400 dilution
for 30 min at room temperature, washed and then incubated with
an avidin-biotin-horseradish peroxidase complex (ABC, Vector
Laboratories Ltd., Peterborough, UK) for 45 min. Sections were
ﬁnally developed with 3,3-diaminobenzidine (DAB/H2O2) for
5 min, washed well in TBS and counterstained with the red ﬂuor-
escent DNA dye propidium iodide (5 mgm l
71 in PBS for 30 min
at room temperature).
Conventional IHC scoring
Each specimen was assessed by a consultant histopathologist (HE-
T, BC) and for each biopsy, 100–400 tumour cells were counted
and the intensity of staining of each cell determined visually and
classiﬁed semi-quantitatively: negative (0)=no staining; 1+=weak
staining; 2+=medium staining; 3+=strong staining, 4+=very strong
staining. The fraction of negative, 1+, 2+, 3+ and 4+ cells was
calculated for each tumour and staining patterns discriminated as
nuclear, cytoplasmic or both.
Image analysis
The intensity of ATase staining was measured using a Lucia Image
Analyser (Nikon UK Ltd., Kingston upon Thames, UK). Duplicate
sections were prepared for each tumour, one section was stained
with primary antibody, and the other with antigen adsorbed serum
(control). Threshold levels were set using the staining of the
control section as a cut off point for each patient. This did not vary
by greater or less than three grey levels within the 255 levels of the
dynamic range of the system. Any staining above this threshold was
counted as positive staining. Ten ﬁelds were counted using the
620 objective lens and for each ﬁeld several parameters were
analysed (see below), the total area of the DAB stained cells
measured and the binary image recorded. Fluorescent green light
(excitation 540/24; dichroic mirror 565; barrier 605/55) was used
to highlight the propidium iodide present in ATase negative cell
nuclei in the ﬁeld and these were thresholded. The ATase positive
binary image was added to the propidium iodide positive binary
image and the total nuclear area recorded. This allowed expression
of all image analysis parameters as a function of total nuclear area
in the subsequent quantitative assessment. The intensity of the
labelling was determined by the computer programme and gave
a grey value from 0 (black) to 255 (white). After capturing the
image on the computer screen, stained areas were identiﬁed as
those regions with a grey value for each pixel below the threshold,
which was set at 230.
The parameters assessed in the detected areas were: (1) Mean
grey: the sum of all the grey levels in the tumour cells divided
by the number of positively staining cells. This was averaged over
all the ﬁelds viewed. (2) Per cent positivity: the number of cells
positively staining for ATase (using the pre-adsorbed control ﬁeld
as the threshold) as a percentage of the total number of cells. (3)
Integrated optical density (IOD): the sum of grey value for each
pixel in the detected area, indicating the total amount of light-
absorbing material in the deﬁned region. (4) Integrated optical
density per area: IOD divided by the total area covered by breast
cancer cells. This value was compared with the level of ATase
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71 of protein) measured by biochemical assay of tissue
extracts. (5) The percentage of cells displaying a grey value of
5100. This gives an estimate of the distribution of highly stained
cells in a sample: the grey value was arbitrarily selected.
Statistical analysis
For the alcohol-ﬁxed series three methods of tumour ATase quan-
titation were used; biochemical assay (quantiﬁed with respect to
cellular protein and DNA content), IHC semi-quantitative scoring
by a histopathologist and IHC followed by computerised image
analysis. Each of these results were compared with a series of estab-
lished prognostic variables available for that particular patient. This
prognostic information included tumour size, grade, histological
type, Manchester score (this combines the node ratio (the percen-
tage of axillary lymph nodes positive for disease divided by the
total number of lymph nodes removed), menopausal status,
tumour grade and whether or not axillary lymph nodes are clini-
cally positive), axillary lymph node status as well as tumour
oestrogen receptor (ER), progesterone receptor (PR), Ki 67 and
epidermal growth factor receptor (EGFR) expression.
Due to the large number of variables being assessed, simple
correlations were used. Spearman’s rank pair correlation was used
to compare the individual data points in ordered rank pairs. The
Kruskal–Wallis one-way ANOVA test was used to compare differ-
ences in the median score between particular groups. For those sets
of data where only two groupings existed (e.g. EGFR: absent or
present) the Mann–Whitney U-test was used. For the comparisons
with the subjective assessment of ATase expression, rank correla-
tions were again used as the score (0, 1+, 2+, 3+, 4+) is
naturally ordered.
RESULTS
Formalin-ﬁxed samples from primary breast tumours
Sixty-one primary breast tumours were analysed. Fifty-ﬁve of the
tumours were ductal carcinomas, six lobular carcinomas, one spin-
dle cell and one medullary carcinoma. Of the ductal carcinomas 12
were histopathological Grade 1, 24 were Grade 2 and 17 were
Grade 3 (Elston, 1984) (Table 1).
ATase staining was seen in most of the tissues studied, only in
two tumours was ATase undetectable. In both tumour and normal
breast, ATase was detected predominantly in the nuclei, however
cytoplasmic expression was also seen. ATase staining varied mark-
edly from one patient to another. There was also heterogeneity
within tumours; in some tumours, most of the cells expressed
the protein in a relatively homogenous pattern, whereas in others,
only a few of the cells were stained either as isolated regions within
the tumours or as isolated cells.
While staining was mainly conﬁned to the nuclei it was not
restricted to tumour cells. In many cases intense staining was seen
in nuclei of endothelial cells and ﬁbroblasts, normal duct epithelial
cell nuclei as well as nuclei of inﬁltrating carcinoma cells (Figure
1). Tumours sometimes had marked lymphocyte inﬁltration and
in these cases, there was intense staining in many lymphocyte
nuclei.
There was no clear pattern of staining intensity that could be
related to histological grade (Table 1). Of the ﬁve lobular carcino-
mas scored, four had high intensity staining and one had moderate
intensity. The single case of spindle cell carcinosarcoma examined
demonstrated high intensity nuclear staining.
Alcohol-ﬁxed samples from primary breast tumours
Sixty-three tumours were analysed and the patient tumour and
staging characteristics are shown (Table 2). Using the biochemical
assay, ATase activity was detected in 62 out of 63 of the breast
tumour samples studied. The median and ranges of ATase activity
by the different methods of assessment are shown (Table 3). Figure
2 shows examples of the ﬁve subjective grades for ATase IHC stain
intensity, along with their controls.
Known prognostic variables were compared with the various
measures of ATase activity using the Kruskal–Wallis one-way
ANOVA. Table 4 shows the patient tumour and staging character-
istics in relation to ATase expression by assay and by two methods
of quantiﬁed IHC. As many of the results were positively skewed
the median values and ranges are given, and log values used to
normalise the data for the statistical analyses. Because two tumours
lacked any ATase activity, the log (x+1) was taken, where x is the
in vitro assay result used in the correlation. Patient information for
all of the variables was not always available hence, the number of
data points available for each variable was not always the same.
Data for 63 patients was available and of these, 54 were alive
with no evidence of disease recurrence at the time of data analysis,
three had relapsed and six had died. Insufﬁcient actual survival
data was therefore available at this stage to assess whether or not
any of the different methods of measuring ATase activity were
correlated with the patient’s ultimate prognosis. No measure of
activity was correlated with lymph node status, tumour grade
and Manchester Score.
While it appeared that ductal tumours had greater intensity of
staining (i.e. lower mean grey) only a relatively small number of
samples with non-ductal tumours were analysed. The subjective
IHC staining intensity score was signiﬁcantly correlated not only
with the ATase activity by protein (P=0.002) and DNA
(P=0.008) but also with mean grey (P50.001), percentage of cells
positive for ATase (P50.001), IOD (P50.001), IOD/area
(P50.001) and number (%) of cells 5100 grey (P50.001). (Table
4)
As most studies cite ATase expression in human tumours with
respect to either DNA or protein content, these two methods of
ATase assessment were compared with each other and were found
to be signiﬁcantly correlated with each other (P50.001).
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Table 1 Relationship between intensity of staining for ATase and histo-
logical grade in ductal carcinoma of the breast. Data represent number of
samples in each category
Intensity of staining
Histological Grade (n) 41253
1 (12) 7 4 1
2 (24) 11 6 7
3 (17) 11 5 1
Negative (0)=no staining; 1+=weak staining; 2+=medium staining; 3+=strong stain-
ing; 4+=very strong staining.
Figure 1 Photomicrographs of IHC staining for ATase in formalin-ﬁxed
breast tumour (6200). (A) Heterogeneous, high level (3+) predominantly
nuclear staining with some weak cytoplasmic staining (+) in both tumour
and surrounding parenchymal tissues. (B) Pre-adsorbed control.
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The chemotherapeutic O
6-alkylating agents are well established in
oncology and are a component of high-dose therapy regimens
currently used in the treatment of metastatic (Peters et al, 1994;
Antman, 2001), and high-risk adjuvant breast cancer (Bengala et
al, 2001). Since ATase is the principal mechanism of cellular resis-
tance to O
6-alkylating agents, its role in tumour aetiology and
response is of considerable interest. Other studies have found that
while ATase is expressed by all breast cell types (Chen et al, 1992),
particularly high levels have been seen in breast cancer cells
(Musarrat et al, 1995). This has been proposed to explain in part
the relative resistance of breast cancer to treatment with O
6-alkylat-
ing agents. In Citron’s study (Citron et al, 1994) while 41% of
normal breast tissue was ATase deﬁcient only 4% of malignant
tissue was. ATase levels were also positively correlated with the
number of inﬁltrated axillary lymph nodes supporting the hypoth-
esis that ATase activity increases with disease progression.
ATase activity has previously been measured in tissue extracts
and this obscures intercellular heterogeneity. This might be an
important issue in the response of individual cells to treatment.
In this present study we have investigated the distribution of ATase
in ﬁxed tissues in relation to biochemical measurements of ATase
activity in tumour tissue extracts and in relation to several clinical
parameters.
Utilisation of both biochemical and IHC techniques was feasible
and practical. Inspection of the histological sections from the
formalin-ﬁxed breast tumours revealed that staining was highly
heterogeneous, from cells completely devoid of ATase to cells with
very intense staining. Marked variation in expression was also seen
between individuals. Many patients demonstrated high staining
intensity in nuclei suggesting high levels of repair protein but in
our study there was no clear evidence that malignant cell nuclei
contained higher levels of protein compared to normal cells within
the same section (e.g. in ﬁbroblasts, endothelial, duct cells and
neutrophils).
The median ATase activity of the 63 tumour samples was
100 fmol mg
71 protein and 6.7 fmol mg
71 DNA which is consis-
tent with previously reported series (Cao et al, 1991; Chen et al,
1992; Musarrat et al, 1995). There were signiﬁcant correlations
between ATase activity by assay expressed as fmol mg
71 DNA
and fmol mg
71 protein, and between the activity expressed per
mg protein with the mean grey, percentage positive and IOD
scores. It was not surprising that many of the quantiﬁed IHC
scores were correlated with each other as many of the values used
in their calculation were common to all of them. It was also of
note that the subjective assessment of the intensity of ATase
expression by IHC was signiﬁcantly correlated with many of the
assay and image analysis systems scores. This provides further
evidence for the usefulness of subjective IHC but also adds further
validity to the use of the computerised system: currently, subjective
assessment alone is used in many areas of clinical practice.
The breast tissue series that were alcohol-ﬁxed were assessed by
both biochemical and IHC techniques. The estimates were then
compared with a series of known prognostic variables. The purpose
of this was not solely to establish if there were correlations of
statistical signiﬁcance per se but also to deﬁne which of these para-
meters might prove useful in future larger multiparametric studies.
However, none of the other variables, including tumour size, grade,
histological type, Manchester score, axillary lymph node status,
tumour oestrogen receptor, progesterone receptor, Ki 67 and
epidermal growth factor receptor expression, correlated with
ATase. Most patients had early, grade 2 ductal carcinomas and this
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Table 2 Patient tumour characteristics
Characteristic No. Median Range
Inter-Quartile
Range
Size of primary tumour (mm) 60 30 0–130 15–40
No. of axillary LN excised 62 14 1–32 10–18
No. of axillary LN inﬁltrated
with tumour
63 0 0–26 0–1
Percentage of excised LN
inﬁltrated with tumour (%)
63 0 0–100 0–10.5
ER positive (%) 59 54 0–99 0–86
PR positive (%) 59 6 0–96 0–48
Ki 67 (%) 59 9 0–87 3.8–27.5
LN=Lymph node; No.=number.
Table 3 Results of different methods of ATase assessment
Patient variable No. Median Range
Inter-Quartile
Range
ATase activity
(fmol mg
71 protein)
63 100 0–1552 54–315
ATase activity
(fmol mg
71 DNA)
63 6.7 0–28 3.7–11.4
Mean grey 44 118 98–142 110–123
Percentage positive 44 39 0.7–84 21–63
IOD 44 4133 117–60077 1408–11009
IOD/area 44 0.37 0.01–1.7 0.17–0.69
No. of cells 5100 grey value 42 8.77 0–51 2.1–18.4
Percentage of cells 5100
grey value (%)
42 1.9 0–34.9 0.47–9.7
IOD=Integrated optical density.
Figure 2 Photomicrographs of IHC staining for ATase in alcohol ﬁxed
breast tumours (6200). (A1) pre-immune serum control (7); (B1) low
(1+); (C1) medium (2+) and (D1) high (3+) staining. A2-D2 show cells
negative for ATase stained with propidium iodide (red ﬂuorescence).
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grade/histological type less accurate.
There have been relatively few similar studies on which to base
an assessment of whether biochemical assay or IHC is the clinically
relevant score. Zaidi et al (1996) compared ATase activity in
human colon tissue by assay, Western blotting and conventional
IHC. They also used a digital image analysis system to quantify
ATase activity and correlated these results with those of the more
‘conventional’ techniques. They found that ATase estimates by
biochemical and Western blots were strongly correlated
(P50.0001). However, the Western blots were quantitated on the
basis of control lanes loaded according to ATase activity and not
total ATase protein and this might not be ideal. Two parameters
of quantitative IHC, integrated grey and mean grey, were also
correlated with each other (P50.002) and with biochemical and
Western blot estimates (P=0.004–0.04).
The present study indicates that there is very extensive heteroge-
neity of ATase staining and that separate biopsies of the same
primary tumour (Figure 4) or biopsies from individual metastases
would not represent ATase levels in the disease as a whole. These
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Table 4 Comparison of tumour characteristics in relation to ATase assessment by assay and two methods of quan-
titative IHC
Variable Frequency
Median ATase
(fmol mg
71 protein)
Median ATase
(fmol mg
71 DNA) Mean grey IOD per area
Histology
Ductal 49 101 7.0 113 0.43
Lobular 8 90 5.9 124 0.2
Other (DCIS, mixed
invasive, mucoid)
6 68 6.7 124* 0.25
Grade
a
1–2 21 81 5.0 118 0.34
3 25 152 8.9 112 0.5
No of LN involved
0 36 88 6.7 119 0.48
1–4 18 156 9.1 117 0.39
44 9 101 3.2 119 0.3
Manchester Score
1 44 99 7.1 117 0.47
2 9 161 6.4 119 0.26
3–4 8 52 4.1 127 0.31
Subjective Score
0 2 18 1.5 126 0.08
1+ 5 101 6.4 123 0.06
2+ 6 90.4 6.4 122 0.31
3+ 24 183 8.4 117 0.36
4+ 8 416** 10.9*** 110{ 0.73{{
aLobular tumours were not graded histologically. *P=0.02, **P=0.002, ***P=0.008, {P50.001, {{P50.001.
Figure 4 Photomicrographs of IHC staining for ATase in alcohol ﬁxed
breast tumours (6200). Variation in IHC staining for ATase in four sepa-
rate breast tumour sites from the same patient. (A) very high (4+); (B)
medium (2+); (C) low (1+) and (D) no staining (7) intensity. In all cases
the staining is mainly nuclear in distribution.
Figure 3 Photomicrographs of IHC staining for ATase in different breast
tumours from the same patient (6200). (A) High ATase staining (3+) in
normal breast; (B) no staining (7) in primary breast tumour; (C) variable
staining in a metastatically inﬁltrated axillary lymph node. Also shows cap-
sular inﬁltration by tumour.
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malignant melanoma where marked variation in ATase staining
was seen among tumour cells within primary tumours, within
the same metastasis, and between separate metastases in the same
patient (Lee et al, 1993; Egyhazi et al, 1997). This heterogeneity
of staining for ATase has been assumed to inﬂuence the variation
of response of metastatic melanomas to chemotherapeutic O
6-alky-
lating agents such as DTIC (Egyhazi et al, 1997). Heterogeneity
might also explain the absence of predictive potential of measuring
ATase activity levels in biopsy homogenates in a Phase II study of
melanoma patients treated with temozolomide (Middleton et al,
1998). It is highly likely that patients whose tumours express low
ATase activity would obtain a better response with O
6-alkylating
agents than those with tumours expressing higher levels. However,
given the heterogeneity of ATase expression, individual, or even
multiple, biopsies and IHC assessment or in vitro assay is unlikely
to be a consistent predictive parameter of response.
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